fbpx

Onyx Biotec IPO GMP

Onyx Biotec IPO GMP grey market premium, review, Subscription, allotment, listing estimate @
Chanakyanipothi.com, a legacy of 31 Years.

India`s Oldest Investment & IPO website.
Most Trusted by Investors across India.

Table of Contents

Onyx Biotec listing Review

Will give detailed review on listing of this IPO

Onyx Biotec IPO allotment Link

What was the last grey market premium of Onyx Biotec IPO?

 For latest GMP, Click

Subscription status of Onyx Biotec IPO

Onyx Biotec Limited IPO
(Closed on 18 Nov 2024)

Price Rs. 61 Lot 2000 shares, Rs. 29.34 Crore

QIB NII x RII x Total x Applications
32.49 602.86 118.26 198.00 103,947 (129.93x)
Amount wise bids recd. Rs. ? Crore
Note: 



What is the business of Onyx Biotec?

Onyx Pharmaceuticals: A Leading Supplier of Sterile Pharmaceutical Products

Onyx Pharmaceuticals has established itself as a trusted name in the healthcare sector, specializing in the production and supply of sterile pharmaceutical products. Over the years, the company has become a prominent supplier to major corporations, including some of the top pharmaceutical companies across India.

Commitment to Quality and Affordability

Onyx is committed to delivering high-quality products at affordable prices. Currently, the company manufactures Sterile Water for Injections and acts as a pharmaceutical contract manufacturer, providing a wide range of Dry Powder Injections and Dry Syrups for both the Indian and international markets. Our products are produced in compliance with global FDA standards and undergo rigorous testing at each stage of production to meet the highest international quality standards.

Industry-Leading Manufacturing and Regulatory Compliance

Its manufacturing process adheres to FDA best practices and is consistently tested to ensure compliance with international standards. The company’s facilities are FDA-certified and our products are regularly tested in-house and at FDA-approved laboratories to guarantee quality and safety.

It focuses on offering end-to-end product development and manufacturing solutions to its clients. Its services also include regulatory dossier preparation and filing for both Indian and global markets, helping its clients navigate the complex regulatory landscape.

State-of-the-Art Manufacturing Facilities

Onyx operates two state-of-the-art manufacturing units in Himachal Pradesh, strategically located to serve both domestic and international markets:

  • Unit I: Bir Plassi, Near Sainimajra, Ropar, Nalagarh Road, District Solan – 174101, Himachal Pradesh, India.
  • Unit II: Village Teliwala, P.O. Manjholi, Tehsil Nalagarh, District Solan – 174101, Himachal Pradesh, India.

Both facilities have been accredited by global regulatory bodies, including the World Health Organization Good Manufacturing Practice (WHO-GMP) certification.

Rigorous Audits and Inspections

Its manufacturing units undergo regular audits and inspections to ensure the highest standards of quality and compliance. In the financial years 2024, 2023, and 2022, the company’s facilities were subject to eight audits at Unit I and seven audits at Unit II, conducted by its clients. Additionally, it underwent three inspections by regulatory authorities, further reinforcing its commitment to maintaining industry-leading quality.

Key Clients and Partnerships

As of May 31, 2024, Onyx’s key clients include some of the most respected names in the pharmaceutical industry, such as:

  • Hetero Healthcare Limited
  • Mankind Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Aristo Pharmaceuticals Private Limited
  • Macleods Pharmaceuticals Limited
  • Mapra Laboratories Private Limited
  • Axa Parenterals Limited
  • FDC Limited
  • Zuventus Healthcare Limited
  • Akums Drugs and Pharmaceuticals Limited
  • Reliance Life Sciences Limited

These partnerships are a testament to Onyx Pharmaceuticals’ growing reputation as a reliable supplier of high-quality sterile pharmaceutical products.

In conclusion, Onyx Pharmaceuticals continues to lead the way in the production and supply of sterile pharmaceutical products, driven by its commitment to quality, regulatory compliance, and customer satisfaction. With state-of-the-art manufacturing facilities, an extensive product range, and a strong portfolio of reputable clients, Onyx is well-positioned to continue its growth in the pharmaceutical sector both in India and globally.

Get more information about the company @ www.onyxbiotec.com

Onyx Biotec IPO Details

IPO opens on  13 November 2024
IPO closes on  18 November 2024
Issue Type Book Built Issue IPO
Issue Size 4810,000 Shares /
Rs 29.34 Crore
* Fresh Issue 4810,000 Shares /
Rs 29.34 Crore
* Offer for Sale – – shares /
Rs. – crore
Market Maker Portion ? Shares
Net offer to Public  Shares/
Rs. Crore
Face Value per share Rs. 10
Price Band Rs. 61
Employee discount  Rs. 0 per share
Retail Lot Size  2000 Shares
Listing will at  NSE SME

Shares offered in IPO

  Shares Rs. (Crore)
QIB (50%) ? ?
NII  (15%) ? ?
RII  (35%) ? ?
Total Shares  ? ?
Retail portion will be
oversubscribed by 
?
Forms
How much Shares to Apply in this IPO?
Min Retail Application 2000 Shares Rs.122000
Min HNI Application  4000 Shares Rs.244000

Who are the Promoters of Onyx Biotec?

The Promoters of the company are Kantilal Jethva and Bhavin Jethwa.

What are the Objects of Onyx Biotec IPO?

The Offer comprises of fresh issue of shares

The Company proposes to utilize the Net Proceeds from the Issue towards the following objects:
1. Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use;
2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;
3. Prepayment or repayment of all or a portion of certain loans availed by the Company; and
4. General Corporate Purposes.

Tentative timetable

IPO opens on 13 November 2024
IPO Closes on 18 November 2024
IPO Allotment on  19 November 2024
Refund Initiation  20 November 2024
Credit of Shares 20 November 2024
Listing on 21 November 2024
Registered Office of the Company
Bir Plassi Near Sainimajraropar, Nalagarh Road, District Solan – 174 101, Himachal Pradesh, India
Who is the Lead Manager of this IPO?
Horizon Management Private Limited

Who is the Registrar to IPO?

MAS SERVICES LIMITED

Onyx Biotec IPO GMP grey market premium, review, Subscription, allotment, listing estimate

Onyx Biotec IPO Financial & Analytical Ratios

Year Total
Income
Net
Profit
EPS RoNW
  Rs.in Crore Rs.in Crore Rs. %
2021-22 44.98 3.35 2.84  
2022-23 39.62 1.84 1.56  
2023-24  53.87 3.30 2.54  
Book Value of the
Share on 31.03.2024
Rs 18.67    
BV of the Share at
cap price after IPO
Rs.      
Offer Price/upper band Rs. 61    

IPO
Key Performance indicators

Price/EPS of 23-24 24.01
Price/BV Ratio 3.26
Price/BV after IPO    


How Onyx Biotec IPO
compares with the Peers?
There is no peer group listed company.

As on date of DRHP FV Total  PE
  Rs. Income Ratio of
    Rs. In Crore  
Onyx Biotec 10    
Suven Pharmachem 1 1051 83.92
JB Chemicals 1 3484 53.63
       
       
       

# This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.

Onyx Biotec IPO Review

Onyx Pharmaceuticals: A Leading Supplier of Sterile Pharmaceutical Products

Onyx Pharmaceuticals has earned a strong reputation in the healthcare sector, specializing in the production and supply of sterile pharmaceutical products. Over the years, the company has become a prominent and trusted supplier to major pharmaceutical corporations, including some of the top-tier companies across India.

IPO Details: Size and Market Outlook

The IPO size is Rs. 29.34 crore, offering 4,810,000 shares. While the size is relatively modest compared to recent IPOs, the company’s strong business model and consistent growth trajectory make the IPO highly attractive. Given the company’s robust performance and promising outlook, the offering has the strong potential to be oversubscribed.

Strong Financial Performance and Reasonable Valuation

Onyx Pharmaceuticals has demonstrated impressive and consistent growth in both topline and bottomline over the past three years, further solidifying its position in the market. With its strong financial track record and solid fundamentals, the shares are offered at a reasonable valuation, making it an appealing investment opportunity.

A Worthwhile Investment Opportunity

Even in the absence of a grey market premium, the Onyx Pharmaceuticals IPO presents a compelling case for investment. With strong growth prospects and a proven business model, this IPO is a solid opportunity for investors looking to tap into the growing pharmaceutical sector.

+ from fundamental angle: Must Apply
+ from grey market angle: Not attractive

Quicklinks

Onyx Biotec IPO GMP today allotment, review?

Onyx Biotec IPO GMP grey market premium

Onyx Biotec IPO FAQs

What is Onyx Biotec IPO
?

This is a SME IPO of 4810000 equity shares of the face value of Rs. 10 aggregating up to Rs.29.34 Crores. The issue is priced at Rs.61 per share. The minimum order quantity is 2000 Shares.

When will Onyx Biotec IPO subscription open?

Onyx Biotec IPO opens on November 13, 2024, and closes on November 18, 2024.

What is the lot size of Onyx Biotec IPO?

Onyx Biotec IPO lot size is 2000 Shares, and the minimum amount required is Rs.122000

How to apply for Onyx Biotec IPO?

You can apply in Onyx Biotec IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don’t offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.

When is Onyx Biotec IPO allotment?

The finalization of Basis of Allotment for Onyx Biotec IPO will be done on November 19, 2024, and the allotted shares will be credited to your demat account by November 20, 2024.

When is Onyx Biotec IPO listing date?

Onyx Biotec IPO listing date is November 21, 2024.

Leave a Reply

Your email address will not be published. Required fields are marked *